Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma

Br J Haematol. 2017 Nov;179(3):503-506. doi: 10.1111/bjh.14226. Epub 2016 Jul 5.
No abstract available

Keywords: ABVD; EPOCH; gray-zone lymphoma; treatment.

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Combined Modality Therapy
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / adverse effects
  • Doxorubicin / therapeutic use
  • Etoposide / adverse effects
  • Etoposide / therapeutic use
  • Humans
  • Lymphoma / diagnosis
  • Lymphoma / drug therapy*
  • Lymphoma / mortality
  • Mediastinal Neoplasms / diagnosis
  • Mediastinal Neoplasms / drug therapy*
  • Prednisone / adverse effects
  • Prednisone / therapeutic use
  • Rituximab / administration & dosage
  • Survival Rate
  • Treatment Outcome
  • Vincristine / adverse effects
  • Vincristine / therapeutic use

Substances

  • Rituximab
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • EPOCH protocol